Introduction of diabetic nephropathy

出自KMU Wiki

(修訂版本間差異)
跳轉到: 導航, 搜索
在2018年3月13日 (二) 17:10所做的修訂版本 (編輯)
Guhjy (對話 | 貢獻)

←上一個
在2018年3月13日 (二) 17:14所做的修訂版本 (編輯) (撤銷)
Guhjy (對話 | 貢獻)

下一個→
第6行: 第6行:
**DCCT (Diabetes Control and Complications Trial) **DCCT (Diabetes Control and Complications Trial)
***Type 1 DM ***Type 1 DM
-***NEJM 1993;329:977: [[The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus]](http://content.nejm.org/cgi/content/short/329/14/977)+***NEJM 1993;329:977: [The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus|http://content.nejm.org/cgi/content/short/329/14/977]
**UKPDS (UK Prospective Diabetes Study) **UKPDS (UK Prospective Diabetes Study)
***Type 2 DM ***Type 2 DM
**Effects on macroangiopathy (cardiovascular disease and atherosclerosis) are less certain **Effects on macroangiopathy (cardiovascular disease and atherosclerosis) are less certain

在2018年3月13日 (二) 17:14所做的修訂版本

  • The most common cause of incident ESRD and the 2nd commonest cause of prevalent ESRD in Taiwan
  • Prevalence
    • 40% in type 1 and 2 DM
    • Because type 2 DM is much more common than type 1 DM, most diabetic nephropathy patients have type 2 DM
  • Importance of hyperglycemia in DN
    • DCCT (Diabetes Control and Complications Trial)
    • UKPDS (UK Prospective Diabetes Study)
      • Type 2 DM
    • Effects on macroangiopathy (cardiovascular disease and atherosclerosis) are less certain